Form 4: ACM Research Director Sells Shares Under 10b5-1 Plan

ACM Research Director Tracy Liu executed pre-planned sales of 60,000 Class A Common Stock shares following option exercises in early March 2026.

Summary

• On March 10, 2026, Tracy Liu, a Director of ACM Research, Inc. (ACMR), exercised stock options to acquire 45,000 shares of Class A Common Stock at an exercise price of $1 per share.
• On the same day, Liu sold 32,216 shares of Class A Common Stock at a weighted average price of $47.06 per share (with prices ranging from $46.67 to $47.51).
• Additionally, on March 10, 2026, Liu sold 12,784 shares of Class A Common Stock at a weighted average price of $48.19 per share (with prices ranging from $47.70 to $48.50).
• On March 11, 2026, Liu exercised stock options to acquire an additional 15,000 shares of Class A Common Stock at an exercise price of $1 per share.
• Also on March 11, 2026, Liu sold 11,623 shares of Class A Common Stock at a weighted average price of $47.81 per share (with prices ranging from $47.13 to $48.12).
• An additional 3,377 shares of Class A Common Stock were sold on March 11, 2026, at a weighted average price of $48.25 per share (with prices ranging from $48.13 to $48.44).
• All reported sales were conducted pursuant to a Rule 10b5-1 trading plan adopted by Tracy Liu on December 4, 2025.
• Following these transactions, Tracy Liu beneficially owns 110,772 shares of ACM Research Class A Common Stock.
• The stock options exercised were fully vested and exercisable, with an expiration date of December 27, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical for executives managing equity compensation, especially given the pre-planned nature of the sales under a Rule 10b5-1 plan.

Positives

• The sales were executed under a pre-established Rule 10b5-1 trading plan, which indicates a structured approach to managing equity compensation rather than opportunistic trading based on non-public information.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived negatively by the market, although these transactions appear to be routine for managing equity compensation.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving the exercise of stock options and subsequent sales under a Rule 10b5-1 plan, are a common practice for executives to manage their equity compensation, diversify their holdings, and address liquidity needs. These types of pre-scheduled transactions are generally viewed as routine and less indicative of management's immediate sentiment about the company's prospects compared to unscheduled sales.

Stakeholder Impact

• Shareholders may observe the insider selling, but the disclosure of a Rule 10b5-1 plan helps mitigate concerns about opportunistic trading, suggesting a pre-planned approach to liquidity management.

Key Dates

Recommendation

The transactions represent routine insider activity under a pre-established 10b5-1 trading plan, which is common for executives managing their equity compensation. It does not provide new fundamental information to alter an investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

ACM Research, ACMR, Insider Trading, Form 4, Stock Sale, Option Exercise, Director Transaction, 10b5-1 Plan, Equity Compensation